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Background: Toll-like receptors (TLR) constitute a highly conserved class of receptors through which the innate
immune system responds to both pathogen- and host-derived factors. Although TLRs are involved in a wide range
of central nervous system (CNS) disorders including neurodegenerative diseases, the molecular events leading from
CNS injury to activation of these innate immune receptors remain elusive. The stress protein heat shock protein 60
(HSP60) released from injured cells is considered an endogenous danger signal of the immune system. In this context,
the main objective of the present study was to investigate the impact of extracellular HSP60 on the brain in vivo.
Results: We show here that HSP60 injected intrathecally causes neuronal and oligodendrocyte injury in the CNS
in vivo through TLR4-dependent signaling. Intrathecal HSP60 results in neuronal cell death, axonal injury, loss of
oligodendrocytes, and demyelination in the cerebral cortex of wild-type mice. In contrast both mice lacking TLR4
and the TLR adaptor molecule MyD88 are protected against deleterious effects induced by HSP60. In contrast to the
exogenous TLR4 ligand, lipopolysaccharide, intrathecal HSP60 does not induce such a considerable inflammatory
response in the brain. In the CNS, endogenous HSP60 is predominantly expressed in neurons and released during
brain injury, since the cerebrospinal fluid (CSF) from animals of a mouse stroke model contains elevated levels of this
stress protein compared to the CSF of sham-operated mice.
Conclusions: Our data show a direct toxic effect of HSP60 towards neurons and oligodendrocytes in the CNS. The fact
that these harmful effects involve TLR4 and MyD88 confirms a molecular pathway mediated by the release of
endogenous TLR ligands from injured CNS cells common to many forms of brain diseases that bi-directionally links
CNS injury and activation of the innate immune system to neurodegeneration and demyelination in vivo.
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Cerebral ischemiaBackground
Inflammation, neuronal injury, and demyelination are
common hallmarks of most central nervous system
(CNS) diseases. Innate immunity activated throughToll-like
receptors (TLRs) contributes to various forms of CNS
injury. TLRs are a highly conserved class of type 1
transmembrane receptors that are involved in regulation* Correspondence: seija.lehnardt@charite.de
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unless otherwise stated.of both innate and adaptive immunity [1]. Thirteen
members of the TLR family (TLR1-13) have been
identified so far in humans, eleven of which are
expressed in mice. Whereas some members of the
TLR family including TLR3, TLR7, and TLR9 locate
to intracellular compartments, other TLRs such as
TLR4 are membrane-bound. TLRs detect conserved
pathogen-associated molecular patterns expressed by
various infectious agents including bacteria, viruses, fungi,
and parasites. However, TLRs are not only activated by
pathogen-associated molecules, but also by host-derived
factors that are supposedly released during tissue injuryntral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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charide (LPS) derived from gram-negative bacteria and
host-derived molecules such as heat shock proteins
(HSPs) including HSP60 and HSP70, extracellular matrix
proteins, such as fibronectin extra domain A and soluble
heparin sulphate, and other proteins including β-defensin
and high mobility group box 1 protein [2-8].
Upon binding to their respective ligands, TLRs initiate
signaling through their intracellular Toll/interleukin-1
(IL-1) receptor (TIR) domains. These interact with other
TIR domains such that, upon activation, each TLR binds
to a specific set of adaptor proteins that also contain
TIR domains. Myeloid differentiation factor 88 (MyD88)
is the universal intracellular adaptor recruited by all
known TLRs except TLR3. In general, triggering of the
well-described complex TLR-associated signaling pathway
results in activation of various downstream effectors
including NF-κB, in turn leading to an inflammatory
response [1] or, occasionally, to cell death [9]. TLRs
are widely expressed in innate immune cells such as
macrophages and microglia in the CNS and dendritic
cells, but also in non-immune cells such as neurons
and epithelial cells [10,11].
Injured tissues release factors including HSPs,
which represent a collection of evolutionarily conserved
proteins induced in response to cellular stress such as heat
shock, nutrient deprivation, or mechanical damage, and
which are considered endogenous danger signals to the
immune system [12-14]. In addition to serving as a cellular
chaperone, extracellular HSP60 directly activates immune
cells including macrophages and dendritic cells through
binding to TLRs and several other membrane receptors
such as CD14 [15,16]. In line with this finding, we observed
in previous work that HSP60 provides a signal to microglia,
the major immune cell of the brain, alerting to the presence
of CNS injury through activation of a TLR4-dependent
pathway in cultured CNS cells [17].
In this study we systematically analyze the impact of
extracellular HSP60 on the brain. Intrathecal HSP60
results in CNS injury including neurodegeneration
and demyelination. These effects require both TLR4 and
MyD88. In contrast to intrathecal application of HSP60,
intrathecal injection of the established pathogen-derived
TLR4 ligand LPS does not affect neuronal or oligodendro-
cyte survival in vivo. However, whereas intrathecal LPS leads
to robust production of proinflammatory molecules in the
brain, CNS injury induced by HSP60 is not accompanied
by such an inflammatory response. HSP60 is predominantly
expressed in injured neurons and oligodendrocytes and is
released during CNS injury such as focal cerebral ischemia
in vivo. Based on our findings we speculate that activation
of the TLR signaling pathway triggered by endogenous
ligands may serve as a damage-specific danger signal
in the CNS.Results
TLR4 expressed in microglia is required for neuronal
injury induced by HSP60
We observed previously that the quantity of viable
neurons recovered from forebrains of mutant lpsd mice, in
which the TLR4 signaling cascade is disrupted as the result
of a naturally occurring mutation, is increased. In this
in vitro context, HSP60 released from injured CNS cells
was identified as an endogenous activator of the TLR4
signaling pathway in microglia, thereby initiating an
inflammatory response and subsequent neuronal injury
[17]. As confirmed by SDS-PAGE followed by immuno-
blotting using antibodies against neuronal nuclei and
synaptophysin, HSP60 induced neurotoxic effects in
co-cultures of cortical neurons from C57BL/6 J mice
in the presence of microglia from C57BL/6 J mice
(Figure 1A). These effects were dose-dependent, as deter-
mined by quantification of NeuN-positive cells (Figure 1B).
In detail, 1 μg/ml HSP60 reduced the relative neuronal
viability significantly by 22.69% (+/−6.16), 10 μg/ml HSP60
by 28.20% (+/−1.81), and 20 μg/ml HSP60 by 50.08%
(+/−0.88) compared to control conditions.
To analyze the role of the microglial receptor TLR4
itself in neuronal injury induced by HSP60, co-cultures
of neurons from cortices of C57BL/6 J mice in the
presence of microglia from C57BL/6 J (wild-type, WT)
mice or TLR4-deficient (TLR4−/−) mice were incubated
with 10 μg/ml HSP60. While 1 μg/ml LPS served as a
positive control for microglia-induced neuronal injury in
this experimental set-up [18], PBS was used as a volume
control. Subsequently, cell cultures were immunostained
with antibodies against neuronal nuclei (NeuN) and IB4
to label neurons and microglia, respectively (Figure 1C).
In cultures supplemented with C57BL/6 J microglia,
incubation with HSP60 led to a significant loss of
neurons. In contrast, neurons in co-cultures containing
microglia lacking TLR4 were not affected by incubation
with HSP60 compared with control conditions. In cell
cultures supplemented with WT microglia, LPS reduced
neuronal numbers to a greater extent than HSP60, as
expected [17]. Quantification of NeuN-positive cells
confirmed these results (Figure 1D). Increased numbers of
TUNEL-positive cells (Figure 1E) and DAPI-stained nuclei
displaying apoptotic hallmarks such as shrinkage and
fragmentation (Figure 1G) in co-cultures containing
WT microglia but not in co-cultures supplemented
with TLR4−/− microglia treated with HSP60 confirmed
toxic effects induced by HSP60 through TLR4 in vitro
(Figure 1F, H). Cultured neurons in the absence of
microglia were not affected by HSP60 treatment (data not
shown), as published before [17]. Notably, the recombinant
HSP60 probe used in this approach was rigorously tested
in terms of LPS contamination (see Materials and
Methods and Discussion), and we excluded the possibility
Figure 1 (See legend on next page.)
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Figure 1 Neurons in the presence of microglia lacking TLR4 are protected against HSP60-induced injury in vitro. (A) Lysates of co-
cultures containing C57BL/6 J neurons and microglia incubated with 10 μg/ml HSP60, 10 μg/ml LPS, or PBS (control) for 3 d were analyzed by
SDS-PAGE and immunoblotting with neuronal nuclei (NeuN) and synaptophysin (SyPh) antibodies. β-actin served as a loading control. Immunoblot
signals were analyzed by densitometry and expressed as fold change to control. One representative experiment of three independent experiments is
shown. (B) Neurons supplemented with C57BL/6 J microglia were incubated with various doses of HSP60 or PBS (control) for 3 d. Subsequently, cells
were stained with NeuN Ab. NeuN+ cells were quantified. Results were statistically expressed as relative neuronal viability by setting the viability of
control cells to 100%. (C-H) Neurons supplemented with C57BL/6 J (WT) or TLR4−/− microglia were incubated with 10 μg/ml HSP60 or PBS (control)
for 3 d, as indicated. 1 μg/ml LPS served as a positive control. (C) Co-cultures were stained with NeuN antibody (red) and with IB4 (green) to mark
neurons and microglia, respectively. (D) NeuN+ cells were quantified. Results were statistically expressed as relative neuronal viability. (E) Co-cultures
were stained with TUNEL assay (red) and (E, G) DAPI (blue). Scale bar, 100 μm. (F) Quantification of TUNEL+ cells/field in cultures displayed in E.
(H) Quantification of DAPI+ nuclei displaying apoptotic hallmarks, as indicated by arrows in cultures shown in G. (B, D, F, H) Results are
presented as mean of 3–4 individual experiments, each condition performed in duplicate +/− SD. **p < 0.01, ***p < 0.001, ****p < 0.0001
(comparison of HSP60-treated groups with control in B; comparison of indicated groups in D; comparison of HSP60- and LPS-treated groups with
control in F and H; two-way ANOVA with Bonferroni-selected pairs).
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in previous work [17].
In summary, neuronal cell death induced by HSP60
requires the expression of TLR4 in microglia in vitro.
Intrathecal administration of HSP60 leads to
neurodegeneration in the CNS
In the context of tissue injury, HSP60 is considered to
serve as a danger signal for the organism because of its
ability to induce a proinflammatory phenotype in innate
immune cells [19]. We aimed at determining the impact
of extracellular HSP60 on the brain in vivo. To this end,
C57BL/6 J mice (WT) were injected with recombinant
HSP60 intrathecally. Serum albumin (SA), a protein
with a similar molecular weight as HSP60, served as
a negative control. Both HSP60 and SA were solved
in water. While LPS, the well-described exogenous
ligand for TLR4 and also solved in water, was used
for comparative analysis [20-22], water alone was used as
a further control condition. No mortality of injected
animals was observed over 3 days. Immunohistochemical
analysis of the cerebral cortex after 3 days revealed a
reduction of NeuN-positive cells in the cerebral cortex of
nine out of eleven HSP60-injected animals compared to
control conditions (Figure 2A). Quantification revealed a
significant loss of 10.1% NeuN-positive cells in the
cerebral cortex of mice injected with HSP60 compared to
the SA-treated control group (Figure 2B). Stereological
analysis of NeuN-positive objects and the percentage
area of NeuN-positive region of interest (ROI) con-
firmed these results (Additional file 1: Figure S1A, B).
In addition, eight out of eleven of the HSP60-treated
mice displayed a distinguishable loss of axons in the
corpus callosum and underlying structures (Figure 2C).
In contrast, neither intrathecal injection of LPS nor
injection of SA resulted in significantly reduced numbers
of neurons or axonal injury compared to the carrier
(water) control group or naive animals, respectively
(Figure 2A-C).To analyze whether the injurious effects induced by
intrathecal HSP60 are associated with apoptosis in the
CNS in vivo, brain sections were stained by TUNEL.
Quantification of TUNEL-positive cells in four represen-
tative brain sections per brain revealed a small (1.8-fold),
but significant increase of apoptotic cells in the cerebral
cortex after application of HSP60 compared to treatment
with SA (Figure 2D), as confirmed by stereological analysis
(Additional file 1: Figure S1C, D). In accordance with these
findings, quantification of DAPI-stained nuclei exhibiting
morphological hallmarks of apoptosis including shrinkage
and fragmentation in the cerebral cortex yielded a signifi-
cant increase of apoptotic nuclei in response to intrathecal
HSP60 compared to control conditions (Figure 2E).
Taken together, intrathecal HSP60 mediates neuro-
degeneration in the cerebral cortex.
Neuronal injury in the CNS after intrathecal injection of
HSP60 requires expression of TLR4 and MyD88
HSP60 signals through TLR4 in microglia and peripheral
immune cells in vitro [1,17]. To test whether TLR4
signaling is involved in neurodegeneration induced by
HSP60 in vivo, TLR4−/− mice were injected intrathecally,
as described above, and compared with HSP60-injected
C57BL/6 J (wild-type, WT) animals. No mortality
was observed in WT and TLR4−/− mice over 3 days.
Immunohistochemical analysis revealed that in contrast to
WT mice, numbers of cortical neurons of TLR4−/− mice
did not differ between the HSP60-injected animals and the
control groups (Figure 2A, B; Additional file 1: Figure S1A,
B). In accordance with these findings, immunostaining of
brain sections from TLR4−/− mice with an antibody against
neurofilament revealed no significant injury or loss of
axonal structures in six out of seven TLR4−/− mice after
intrathecal application of HSP60 compared to mice treated
with SA (Figure 2C). Also, in contrast to the increased
numbers of TUNEL-positive cells in WT animals
described above, numbers of TUNEL-positive cells in
brains of TLR4−/− mice were unchanged after injection of
Figure 2 HSP60 triggers neurodegeneration in the cerebral cortex dependent on TLR4 and MyD88 in vivo. (A) Forty micrograms of
HSP60 or 40 μg of SA were injected intrathecally into 8–12 week-old C57BL/6 J (WT, HSP60 n = 11, SA n = 8), TLR4−/− (HSP60 n = 11, SA n = 8),
and MyD88−/− (HSP60 n = 11, SA n = 8) mice. Naïve mice received no injection (WT n = 6, TLR4−/− n = 4, MyD88−/− n = 4). Injection of LPS into WT
mice served as a positive control for TLR4 activation (n = 10). Injection of water into WT mice served as a carrier control for LPS, HSP60, and SA
injection (n = 7). After 3 d, the cerebral cortex was analyzed by immunostaining with NeuN antibody. Scale bar, 100 μm. (B) Quantification of
cortical NeuN+ cells of WT, TLR4−/−, and MyD88−/− mice injected intrathecally, as described above. Median, Mann–Whitney U test for indicated
groups. (C) Brain sections containing the corpus callosum of WT, TLR4−/−, and MyD88−/− mice injected as described above were immunostained
with a neurofilament antibody. Scale bar, 50 μm. Quantification of TUNEL+ cells (D) and DAPI-stained nuclei displaying apoptotic hallmarks including
irregular shape, shrinkage, and fragmentation (E) in representative sections of the cerebral cortex of WT, TLR4−/−, and MyD88−/− mice injected
intrathecally with HSP60 or SA, as indicated. (D, E) Median, Mann–Whitney U test for indicated groups.
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Additional file 1: Figure S1C, D).
The role of the TLR adapter MyD88 in HSP60-induced
neurodegeneration in vivo was investigated by injecting
HSP60 into MyD88−/− mice, as described above, and
compared with HSP60-injected C57BL/6 J (WT) animals.
No mortality was observed in MyD88−/− and WT mice
over 3 days. In contrast to WT mice, mice lacking MyD88
were not significantly affected by injection of HSP60
regarding neuronal survival in the cerebral cortex
(Figure 2A, B; Additional file 1: Figure S1A, B). Numbers
of cortical neurons of MyD88−/− mice injected with
HSP60 were significantly higher than the neuronal
numbers of WT animals injected with HSP60 (p < 0.05).
Although a trend of enhanced TUNEL positivity in
MyD88−/− mice after HSP60 treatment was observed
(Figure 2D), numbers of TUNEL-positive cells did not
differ significantly between MyD88−/− mice that received
intrathecal HSP60 and the respective control animals
(Figure 2D; Additional file 1: Figure S1C, D). Also,
axonal structures within the cerebral cortex of MyD88−/−
mice were not affected by intrathecal HSP60 compared
with control conditions (Figure 2C).
In accordance with these findings, quantification of
DAPI-stained nuclei in the cerebral cortex of TLR4−/−
and MyD88−/− mice revealed no differences in numbers of
nuclei displaying morphological hallmarks of apoptosis
between animals injected with HSP60 intrathecally and
control animals (Figure 2E).
In summary, neurodegeneration following intrathecal
injection of HSP60 requires TLR4 and MyD88.
CNS injury following intrathecal injection of HSP60
includes demyelination dependent on TLR4 and MyD88
Our previous studies had revealed that activation of
TLR4 by LPS results in oligodendrocyte injury in vitro
[23]. To test the ability of the endogenous ligand HSP60
to induce injury of oligodendrocytes and/or myelin
in vivo, we analyzed brain sections of mice injected
with HSP60 or SA intrathecally, as described above,
by immunohistochemistry using antibodies directed
against adenomatous polyposis coli (APC) and myelin
basic protein (MBP) to mark oligodendrocytes and
myelin, respectively (Figure 3A, C). All animals from
the C57BL/6 J strain treated with HSP60 showed a
major loss of oligodendrocytes in the cerebral cortex
compared to mice injected with SA (Figure 3A).
Quantification of oligodendrocytes confirmed these results
(loss of 65.34% APC-positive cells, Figure 3B and
Additional file 1: Figure S1E, F). While sections from
SA-injected animals after 3 days displayed a uniform
abundant distribution of MBP in the cerebral cortex,
injection of HSP60 resulted in a reduced immunoreactiv-
ity against MBP in all treated animals (Figure 3C), asconfirmed by analysis of the mean MBP-positive fluores-
cence intensity (Figure 3D).
To confirm the role of TLR4 and MyD88 in oligodendro-
cyte injury and demyelination induced by HSP60 in vivo,
TLR4−/− and MyD88−/− mice were included in the experi-
ments described above (Figure 3A-D). None of the TLR4−/−
and MyD88−/− mice that received HSP60 showed loss of
oligodendrocytes or damage of myelin-positive structures
compared to animals that received SA (Figure 3A, C).
Quantitative analysis of the surviving oligodendrocytes
(APC-positive cells, Figure 3B and Additional file 1:
Figure S1E, F) and assessment of the mean MBP-positive
fluorescence intensity (Figure 3D) in the cerebral cor-
tex of TLR4−/− and MyD88−/− mice confirmed these
results. Also, total numbers of APC-positive cells in
the cerebral cortex of TLR4−/− and MyD88−/− mice treated
with HSP60 were increased compared with numbers
in WT animals injected with HSP60 (Figure 3B and
Additional file 1: Figure S1E, F).
These data prove a toxic effect of intrathecal HSP60
towards oligodendrocytes and myelin that requires a
functional TLR4 and MyD88 pathway in vivo.
HSP60 mediates loss of oligodendrocyte precursor cells
dependent on TLR4 expressed in microglia in vitro
To further investigate injurious effects of HSP60 on
oligodendrocyte precursor cells in vitro, cells of the
oligodendrocyte precursor line Oli-neu alone or in the
presence of microglia were incubated with increasing
concentrations of HSP60 for 3 days. Subsequently, cells
were immunostained with an APC antibody to mark
Oli-neu cells. Quantification of APC-positive cells
co-cultured with microglia revealed a dose-dependent
reduction of the relative viability of Oli-Neu cells
induced by HSP60 (Figure 4A). In contrast, incubation of
Oli-neu cells alone with HSP60 did not affect relative
oligodendrocyte viability compared with control conditions,
even when HSP60 was used at the highest concentration of
20 μg/ml (Figure 4A). To analyze the role of TLR4 in
oligodendrocyte precursor injury induced by HSP60,
co-cultures of Oli-neu cells in the presence of microglia
from C57BL/6 J (WT) mice or TLR4-deficient (TLR4−/−)
mice were incubated with 10 μg/ml HSP60. 1 μg/ml LPS
served as a positive control for microglia-induced injury
of oligodendrocyte precursors in this experimental set-up
[23]. Subsequently, cell cultures were immunostained
with APC antibody and IB4 to label Oli-neu cells and
microglia, respectively (Figure 4B). In cultures supple-
mented with WT microglia, incubation with HSP60 led to
a significant loss of Oli-neu cells. In contrast, Oli-neu cells
in co-cultures containing microglia lacking TLR4 were not
affected by incubation with HSP60 compared to con-
trol conditions. In cell cultures supplemented with
WT microglia, LPS also reduced numbers of Oli-neu
Figure 3 HSP60 induces demyelination dependent on TLR4 and MyD88 in vivo. Three days after intrathecal injection of 40 μg HSP60 or
40 μg SA (control) coronal brain sections of C57BL/6 J (WT, HSP60 n = 4, SA n = 4), TLR4−/− (HSP60 n = 4, SA n = 4), and MyD88−/− (HSP60 n = 4,
SA n = 4) mice were evaluated for the myelination status. (A) Immunostaining of the cerebral cortex of WT, TLR4−/−, and MyD88−/− mice with an
antibody directed against APC. Scale bar, 50 μm. Cut-outs at higher power from the micrographs. Scale bar, 50 μm. (B) Quantification of APC+ cells
in the cerebral cortex of WT, TLR4−/−, and MyD88−/− mice. Median; p values were determined for indicated groups by Mann–Whitney U test.
(C) Immunostaining of the cerebral cortex of injected WT, TLR4−/−, and MyD88−/− mice with an antibody against MBP. Scale bar, 50 μm. Cut-outs at
higher power from the micrographs. Scale bar, 50 μm. (D) Analysis of mean MBP+ fluorescence intensity in the cerebral cortex of WT, TLR4−/−, and
MyD88−/− mice. Median, Mann–Whitney U test for indicated groups.
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cells confirmed these results (Figure 4C).
Taken together, extracellularly applied HSP60 leads to
injurious effects in oligodendrocyte precursor cells
dependent on TLR4 expressed in microglia in vitro.
HSP60 does not result in major glial activation or
proliferation in the cerebral cortex
Glial cells, in particular microglia and astrocytes, contribute
to various forms of CNS injury [24]. To gain further insight
into the impact of glia on the response to intrathecal
HSP60 in vivo, brain sections from C57BL/6 J mice injected
intrathecally with HSP60 or SA were immunostained with
antibodies directed against Iba1 and GFAP to analyze
microglia and astrocytes, respectively. No obvious morpho-
logical signs of glial activation were observed in the cerebral
cortex of HSP60-treated mice (Figure 5A, D). Also, assess-
ment of the mean fluorescence intensity of Iba1- and
GFAP-positive cells revealed no significant differences
between animals injected with HSP60 and control animals
(Figure 5B, E). In line with these findings, quantification ofIba1- and GFAP-positive cells in the cerebral cortex re-
vealed no differences in cell numbers between animals that
received intrathecal HSP60 and animals treated with the
control protein SA (Figure 5C, F). Likewise, differences in
the morphology or number of CD11b-positive cells in the
cerebral cortex of animals injected with SA and animals
treated with HSP60 were not detected (data not shown).
To further investigate whether intrathecal HSP60 causes
proliferation of cells in the cerebral cortex, brain sections of
the injected animals were immunostained with the intrinsic
proliferation marker Ki67 (Figure 5G). No Ki67 reactivity
was detected in the cerebral cortex of HSP60-treated mice
or animals injected with SA. However, Ki67-positive cells
were present regularly in the subgranular zone of the
hippocampal dentate gyrus, in which proliferation of
neuronal precursors occurs, as expected.
In comparison to LPS, intrathecal HSP60 does not
provoke a robust inflammatory response in the CNS
Activation of TLRs expressed in glial cells by their cognate
ligands typically results in a strong inflammatory response
Figure 4 HSP60 induces loss of Oli-neu cells in the presence of microglia expressing TLR4 in vitro. (A) Oli-neu cells alone or supplemented
with neonatal microglia from C57BL/6 J mice were incubated with various doses of HSP60 or PBS (control), as indicated, for 3 d. Subsequently, cell
cultures were stained with APC antibody to mark oligodendrocyte precursor cells. APC+ cells were quantified, and results were statistically expressed
as relative viability of Oli-neu cells by setting the viability of control cells to 100%. (B) Oli-neu cells co-cultured with neonatal microglia derived from
C57BL/6 J (WT) or TLR4−/− mice were incubated with 10 μg/ml HSP60 or PBS (control), as indicated. 1 μg/ml LPS served as a positive control. After 3
d, co-cultures were fixed and stained with both APC antibody (red) and with IB4 (green) to mark oligodendrocyte precursor cells and microglia,
respectively. Scale bar, 100 μm. (C) APC+ cells were quantified, and results were statistically expressed as relative viability of Oli-neu cells
by setting the viability of control cells to 100%. (A, C) Results are presented as mean of 3 individual experiments with each condition performed in
duplicate +/− SD. ***p < 0.001; ****p < 0.0001 (for the comparison of HSP60-treated groups with the control group in A; for the comparison of
indicated groups in C; two-way ANOVA with Bonferroni-selected pairs).
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In order to determine HSP60’s capacity to induce inflam-
mation in the CNS, mouse brains challenged with HSP60
were analyzed for the expression of proinflammatory
mediators. To this end, C57BL/6 J mice were injected
intrathecally with HSP60 or SA. Further control groups
received sham surgery or were injected intrathecally with
LPS as a positive control for TLR4 activation. After 6 h,
12 h, and 72 h, whole brain lysates were analyzed by
quantitative real-time PCR using primers specific for
genes encoding various proinflammatory cytokines and
chemokines that are typically involved in the innate
immune response [26,27], as indicated (Figure 6A).
Whereas intrathecal injection of LPS resulted in a robust
upregulation of most of the tested proinflammatory genes
at at least one time point, intrathecal injection of HSP60
did not change the expression levels of the tested genes
during the whole round of observation with the exception
of TGF-β (0.01-fold, p < 0.001) and IL-23 (0.76-fold,
p < 0.05), which were significantly downregulated com-
pared to SA injection after 6 h (Figure 6A).
Analysis of protein content in brain lysates from
mice injected with HSP60 was performed using the
bead-based immunoassay FlowCytomix and ELISA. Theresults confirmed that, in contrast to LPS, intrathecal
HSP60 did not cause significant changes in the content of
proinflammatory mediators, such as IL-6, CXCL1, and
CCL5, compared to control conditions (Figure 6B).
In the CNS, reactive oxygen species such as nitric
oxide (NO) and further diverse neurotoxic metabolites
contribute to neuronal and oligodendrocyte injury in
inflammatory states [28,29]. To test whether intrathecal
HSP60 and subsequent CNS injury are associated with
the induction or accumulation of reactive oxygen species
and neurotoxic metabolites, C56BL/6 J mice were injected
intrathecally with HSP60. Control groups received sham
surgery, SA, or LPS for comparative analysis. After 12 h,
brain lysates were tested for mRNA expression of
neurotoxic metabolite producing enzymes including
indoleamine 2,3-dioxygenase (Ido), cyclooxygenase 2
(Cox-2), glutaminase (Gls), and inducible nitric oxide
synthase (iNOS) by quantitative real-time PCR (Figure 6C),
and were analyzed for NO content using the Griess reac-
tion (Figure 6D). Neither mice injected with HSP60 nor
animals injected with SA displayed changes in the expres-
sion levels of any of the tested candidate genes compared
to sham animals. In contrast, intrathecal injection of LPS
led to a 2.4-fold increase of Cox-2 and a 7.4-fold increase
Figure 5 (See legend on next page.)
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Figure 5 Intrathecal HSP60 does not result in major glial activation or proliferation in the cerebral cortex. Three days after intrathecal
injection of 40 μg HSP60 or 40 μg SA (control) coronal sections of C67BL/6 J mouse brains were evaluated in terms of glial morphology and
numbers. (A) Immunostaining of the cerebral cortex of C67BL/6 J mice (HSP60 n = 8, SA n = 5) with an Iba1 antibody. Scale bar, 100 μm, insets
50 μm. (B) Measurement of mean Iba1+ fluorescence intensity (HSP60 n = 4, SA n = 4). (C) Quantification of Iba1+ cells (HSP60 n = 8, SA n = 5).
(B, C) Median, Mann–Whitney U test for the comparison of the HSP60-injected group with the SA-treated (control) group. (D) Immunostaining of
the cerebral cortex of C67BL/6 J mice (HSP60 n = 7, SA n = 8) with a GFAP antibody. Scale bar, 100 μm, insets 50 μm. (E) Measurement of mean
GFAP+ fluorescence intensity (HSP60 n = 4, SA n = 4). (F) Quantification of GFAP+ cells (HSP60 n = 7, SA n = 8). (E, F) Median, Mann–Whitney U
test for the comparison of the HSP60-injected group with the SA-treated (control group). (G) Representative micrographs of the cerebral cortex
immunostained with Iba1, GFAP, and Ki67 antibodies to mark microglia, astrocytes, and proliferating cells, respectively (HSP60 n = 4, SA n = 4).
The subgranular zone of the hippocampal dentate gyrus served as a positive control for Ki67 reactivity. Scale bar, 100 μm.
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conditions. However, no significant changes of NO con-
tent in the brain were detected in response to intrathecal
HSP60 or LPS compared to control injections.
Predominant expression of HSP60 in CNS neurons is
upregulated in response to injury
Endogenous activators of the innate immunity such as
HSP60 are evolutionary conserved molecules with the
common feature of being foreign to the extracellular
environment [30]. To determine the expression pattern of
HSP60 in response to injury in the CNS, we made use of
focal cerebral ischemia, a mouse model for stroke. Cerebral
cortices of both stroked and sham-operated (control) mice
were individually analyzed by immunohistochemistry using
an antibody directed against HSP60 at 24 h after middle
cerebral artery occlusion (MCAo). Although HSP60 is
thought to be expressed ubiquitously [31], expression of
HSP60 in the brains of sham-operated mice and in the
contralateral unaffected hemispheres of animals treated
with MCAo was detected predominantly in neurons
(Figure 7A). In oligodendrocytes only weak or none
immunoreactivity against HSP60 was observed. Neither
microglia nor astrocytes displayed detectable HSP60
expression. In mice treated with MCAo expression of
HSP60 in neurons and less pronounced in oligodendro-
cytes of the infarct area and the lesion-associated region
of the ipsilateral brain hemisphere was clearly enhanced
as compared to sham-operated animals and compared
to the contralateral hemisphere of the MCAo-treated
animals (Figure 7A). Stereological assessment of HSP60-
positive objects and the percentage area of HSP60-positive
region of interest (Additional file 2: Figure S2A, B) and ana-
lysis of the mean fluorescence intensity of HSP60 reactivity
(Additional file 2: Figure S2C) confirmed these results.
Expression of HSP60 was not detectable in microglia or
astrocytes of MCAo-operated mice (Figure 7A). Analysis of
brain lysates by SDS-PAGE revealed increased expression
of HSP60 at one day after MCAo compared to sham-
operated mice (Figure 7B), as expected [32,33]. To further
explore the expression of HSP60 in CNS cells, lysates of
cultured cortical neurons, microglia, and Oli-neu cells were
analyzed by SDS-PAGE using an antibody directed againstHSP60 (Figure 7C). While a pronounced and weak expres-
sion signal for HSP60 was detected in naïve neurons and
oligodendrocyte precursors, respectively, no immunoreac-
tivity was observed in preparations of naïve microglia.
Expression of HSP60 was increased in neurons incubated
with the TLR7 ligand imiquimod, which is known to
induce cell-autonomous apoptosis in neurons [34],
compared to unstimulated control conditions. Similarly,
HSP60 expression was increased in Oli-neu cells incubated
with imiquimod or the cytotoxin staurosporine, compared
to untreated control conditions. In microglia, weak expres-
sion of HSP60 in response to imiquimod treatment was
detected (Figure 7C).
These results show that HSP60 is predominantly
expressed in neurons and that its expression is increased
after injury.
Endogenous HSP60 is released in CNS injury
HSP60 predominantly localizes to mitochondria [31]. In the
CNS, its intracellular expression is increased in response to
various types of injury [35,36]. Along the same line, we have
observed an increase of HSP60 expression in CNS neurons
in response to ischemic injury in vitro and in vivo. For
endogenous HSP60 to be capable of serving as an injury-
related signal in the brain, it must exist extracellularly.
Thus, we quantified levels of HSP60 protein in the CSF of
mice treated with focal cerebral ischemia using ELISA and
compared them to CSF of the sham-operated group
(Figure 8). Whereas HSP60 protein was undetectable or
present in only minute amounts in the CSF of control
animals, the CSF of all mice treated with MCAo contained
measurable and higher levels of HSP60. Although statistical
significance was not reached within our experimental
set-up, these results suggest that HSP60 is released
during injurious processes in the CNS in vivo, thereby
gaining the capability of serving as a danger signal in
CNS injury.
Discussion
Heat shock proteins released from damaged cells are key
molecules during injury and inflammation and are capable
of activating immunity. Accordingly, we showed in
previous work that dying CNS cells release HSP60
Figure 6 (See legend on next page.)
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Figure 6 Compared to LPS, intrathecal HSP60 does not induce considerable inflammation in the CNS. (A) C57BL/6 J mice were injected
intrathecally with 40 μg HSP60 (n = 4), 40 μg SA (control, n = 4), or 10 μg LPS (n = 4). After 6 h, 12 h, and 72 h brain lysates were analyzed for the
expression of various genes encoding proinflammatory molecules, as indicated, by qPCR. Normalized values (ΔCT) per animal with the median of
the respective group; *p < 0.05, **p < 0.005, ***p < 0.001; ANOVA of log2 transformation followed by Bonferroni-selected pairs; versus SA. Fold
increase to SA was calculated with the median. (B) C57BL/6 J mice were injected intrathecally with 40 μg HSP60 (n = 4), 40 μg SA (control, n = 4),
or 10 μg LPS (n = 4). Sham-operated animals served as a further control group (n = 4). After 12 h brain lysates were analyzed for the expression
levels of proinflammatory proteins, as indicated, by multiple analyte detection and Il-1β ELISA. Median; *p < 0.05, **p < 0.005; Kruskal-Wallis
followed by Dunn’s selected pairs; versus sham. (C, D) C57BL/6 J mice received sham surgery (n = 4) or were injected intrathecally with 40 μg
HSP60 (n = 4), 40 μg SA (n = 4), or 10 μg LPS (n = 4). After 12 h brain lysates were analyzed for (C) mRNA expression of various enzymes associated
with the production of neurotoxic metabolites, as indicated, and (D) the content of nitrite (NO). (C) Levels of mRNA expression were determined
by qPCR and expressed as ΔCT per animal with the median; ***p < 0.001; ANOVA of log2 transformation followed by Bonferroni-selected pairs;
versus sham. (D) Determination of the amount of NO by Griess’ reaction; Median, Kruskal-Wallis test followed by Dunn’s selected pairs.
Rosenberger et al. Molecular Neurodegeneration  (2015) 10:5 Page 12 of 19in vitro, thereby leading to activation of microglia and
subsequent neuronal injury [17]. In contrast to the
ongoing intensive research on the HSP60’s effects on
cells of the peripheral immune system, the biological
impact of extracellular HSP60 on the CNS in vivo was
undetermined so far. In the present study we demonstrate
that intrathecal HSP60 mediates neurodegeneration and
demyelination in vivo.
In cerebral ischemia, TLRs contribute to CNS injury
[37,38] and their expression was detected mainly in
activated glia [38]. These findings suggest that TLRs
expressed in glia may recognize endogenous TLR ligands
released during ischemic brain injury. However, the identity
of such endogenous ligands is unknown. On the basis of
our data it is tempting to speculate that HSP60 might be at
least one of them. Our finding that HSP60 is overexpressed
in injured neurons and oligodendrocytes and can be
detected extracellularly in response to CNS injury
match with the results from several other studies. For
example, the amount of HSP60 in the serum of patients
with a cerebral infarct is increased [39]. Also, soluble
HSP60 was detected in the CSF of children suffering from
traumatic brain injury [40].
At this stage, it remains unknown how HSP60 applied
intrathecally exerts the observed degenerative effects in
the brain. However, as described for other large proteins,
intrathecal HSP60 may enter the brain tissue via receptor-
mediated cellular uptake and intercellular transfer in
principle [41]. Several studies have reported intrathecal
delivery of large proteins to the brain parenchyma.
Moreover, in CNS diseases including stroke and neu-
rodegenerative lysosomal storage disorders intrathecal
application of such proteins can result in deep penetration
into the brain tissue and is functionally effective [42]. Also,
we cannot rule out that intrathecal HSP60 leads to an
inflammatory response that in turn causes degenerative
effects in the brain paremchyma. Furthermore, it is
unclear how much HSP60 is effectively released within
the brain parenchyma at the site of injury in the context
of CNS disorders and what the local concentration
maxima are. The concentration of HSP60 used in thecurrent study was based on our previous work in vitro
and on our experience with a ligand for TLR2 in vivo
[43,44], and must be considered supraphysiologic. Our
study is a proof of principle regarding the effects of
HSP60 in the brain, and future work will be required to
determine key properties of HSP60 as a signaling molecule
in the brain and the pathophysiological concentration of
HSP60 that is involved in CNS damage.
Glial activation regularly occurs in the setting of
neuronal injury and demyelination [24]. Microglia
expressing TLR4 and releasing nitric oxide are required in
neuronal injury induced by extracellular HSP60 in vitro
[17]. However, although HSP60 activates the immune
response in the periphery [45,46], results of our present
study indicate that intrathecal HSP60 does not result in
major activation or proliferation of glia and does not
induce a considerable inflammatory response, as provoked
by LPS, in the cerebral cortex in vivo. Notwithstanding,
subtle activation of glial cells in vivo likely occurs, as these
cells constantly monitor their microenvironment and
respond to injury in their proximity [24]. We cannot rule
out that specific inflammatory molecules different from
the ones tested accumulate in response to intrathecal
HSP60 or that the period of observation in our set-up was
too short. Also, the expression of distinct proinflammatory
mediators in the brain may vary depending on the
concentrations of intrathecal HSP60, which we did not
test. Although the release of inflammatory molecules from
microglia activated by soluble danger signals has been
demonstrated in vitro [17,47], the situation in the CNS
in vivo is likely a lot more complex due to interaction of
different cell types and further regulatory mechanisms.
Indeed, recent studies on peripheral immune cells suggest
that distinct inflammatory responses induced by HSP60
via TLR4 and TLR2 are dependent on the respective
pathological context in vivo [48,49]. Also, mechanisms
that operate directly through neurons and oligodendro-
cytes have to be taken into account. TLR3, TLR8, and
TLR7 mediate cell-autonomous neuronal and axonal
injury upon activation [44,50,51]. Although the expression
of TLR4 in neurons is discussed controversely [52,53] and
Figure 7 (See legend on next page.)
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Figure 7 HSP60 is predominantly expressed in CNS neurons and is upregulated after injury. (A) Immunofluorescence photomicrographs
of the infarct (ipsilateral; ipsi and contralateral; co) and lesion-associated region (lar) in brains of C57BL/6 J mice at 1 d after MCAo. Sham-operated
animals served as a negative control. Tissues were double-stained with anti-Iba1, anti-GFAP, anti-APC and anti-NeuN antibodies to mark microglia,
astrocytes, oligodendrocytes, and neurons, respectively, and with anti-HSP60. Nuclei were stained with DAPI. Scale bar, 100 μm. Cut-outs at higher
power from the micrographs. Scale bar, 10 μm. (B) Ipsi- and contralateral hemispheres of C57BL/6 J mice at 1 d after MCAo and of the respective
sham-operated animals were analyzed by SDS-PAGE and subsequent immunoblotting with an HSP60 antibody. β-actin served as a housekeeping
control. (C) Lysates of cultured neurons and microglia, both incubated with 10 μg/ml imiquimod or PBS (control) for 12 h and 3 h, respectively, and
lysates of Oli-neu cells incubated with 10 μg/ml imiquimod, 1 μM staurosporine (St), or PBS (control) for 3 h were analyzed by SDS-PAGE and
subsequent immunoblotting with an HSP60 antibody. β-actin served as a housekeeping control.
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cytes was detected [23], TLR4 may be up-regulated and
activated in these cells in the presence of HSP60 in vivo.
However, in this case yet unidentified factors that have an
impact on TLR activation must exist, since neurons and
oligodendrocytes alone are not affected by HSP60 in vitro.
Also, it cannot be ruled out that the observed degenerative
effects in vivo are not mediated by direct interaction
between HSP60 and TLRs, but rather are caused by
unknown secondary effects following the intrathecal
application of HSP60.
It seems intriguing that activation of the same receptor
and signaling molecule in the brain, namely TLR4
and MyD88, results in a different outcome regarding
injury and inflammation depending on the ligand used.
Intrathecal injection of the exogenous ligand LPS caused a
robust inflammatory response but no CNS injury, while
intrathecal injection of the endogenous ligand HSP60 ledFigure 8 CSF of stroked mice contains increased amounts of
HSP60. CSF from C57BL/6 J mice treated with focal cerebral ischemia
(MCAo, n = 4) and from control subjects (sham, n = 3) was assayed by
ELISA using an antibody directed against HSP60. Results are presented
with the median. Statistical analysis was performed using the
Mann–Whitney U test, p = 0.0651 for the comparison of both groups.to neurodegeneration as well as demyelination but failed
to induce a comparable inflammatory response in the
brain as provoked by LPS. Although it is unknown, how
inflammation and neuronal damage mediated by TLRs are
related in the brain different pathways downstream
of TLR4 and MyD88 may be activated in the CNS,
depending on the ligand. Furthermore, taking into
account the observed trend towards enhanced
TUNEL+ positivity in brains of MyD88-deficient mice,
but not in brains of TLR4-deficient animals after HSP60
treatment (see Figure 2D), we cannot rule out at this stage
that other molecules downstream of TLR4 besides
MyD88 contribute - at least in part - to HSP60-induced
CNS injury. SARM, which is preferentially expressed in
neurons and may play a crucial role in neuronal and
axonal injury [54], is a possible candidate molecule.
At least in the periphery HSP60 triggers a multifaceted
process, dependent among others, on its interaction
with other receptors [55,56]. Also, TLR4 exerts not
only detrimental but also regenerative effects upon
injury [57]. The interaction between HSP60 and TLR4
may therefore not only cause damage in the CNS, but
may also induce anti-inflammatory and neuroprotective
effects [58,59].
Signaling by HSPs has long been the subject of con-
siderable debate [45]. In particular it was discussed
that the effects of HSP60 on macrophages were likely
to be caused by LPS contaminating recombinant
HSP60 preparations [60]. We showed previously that
neurotoxic effects mediated by HSP60 are not caused by
LPS [17]. Notably, we used a low-endotoxin HSP60 batch
in our studies, and this preparation was used after dilution
to such an extent that the theoretical maximal content of
LPS was by far not sufficient to induce neuronal injury
in vitro [17]. We show here that intrathecal LPS itself does
not affect neuronal and oligodendrocyte survival in the
cerebral cortex - in contrast to recombinant HSP60, which
leads to degenerative processes in vivo.
Besides TLR4, other receptors are involved in HSP60-
induced inflammatory effects. LOX-1 serves as a receptor
for HSP60 in dendritic cells in lung inflammation [61].
The microglial TREM2 receptor was identified as an
HSP60-binding protein, whose binding resulted in an
increase in phagocytosis [62]. Finally, not only TLR4 but
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is unknown whether the receptors named above are
involved in CNS injury in vivo. Also, other endogenous
ligands besides HSP60 are released from both injured
peripheral and CNS cells. For example, β-defensin, and
HSP70 activating TLR2 and TLR4 [3,6], but also ligands
of other receptors, such as let-7 miRNA activating TLR7
[44] and HMGB1 binding to RAGE [63], are host-derived
molecules involved in inflammation and tissue damage. It
is conceivable that many more yet unidentified molecules
are released during tissue injury. However, since the
identity of such molecules and the associated bio-
logical processes are still poorly defined, one can only
estimate at this stage to which extent their interaction
is biologically relevant in a given CNS disorder.
Conclusions
In summary, extracellular HSP60 mediates CNS injury
in vivo through a TLR4- and MyD88-dependent path-
way. On the basis of our previous results obtained
in vitro and of our current studies in vivo we propose a
molecular mechanism by which CNS injury leads to the
release of HSP60, which in turn activates TLR4 signaling
in the brain. As a consequence, further neurodegenera-
tion and demyelination ensues. Both neurodegeneration
and demyelination, which are common hallmarks of
various CNS disorders, may be thus bi-directionally
linked with an ancient host response system through
conserved molecules such as the HSPs and innate immune
receptors such as the TLRs.
Material and methods
Animals
C57BL/6 J mice were purchased from Charles River,
Sulzbach, Germany. TLR4−/− and MyD88−/− mice were
generously provided by Dr. S. Akira (Osaka University,
Department of Host Defense, Osaka, Japan). All animals
were maintained according to the guidelines of the
committee for animal care. In detail, mice were housed in
groups with chip bedding and environmental enrichment
on a 12 h light/dark cycle with ad libitum access to water
and food (standard chow). All experiments were
conducted in accordance with the European directive
on the protection of animals used for scientific purposes
and approved by the institutional review committee
Landesamt für Gesundheit und Soziales, Berlin, Germany
(LAGeSo registration TVA G 0175/07).
Primary culture of neurons and microglia
Purified microglia were generated from forebrains of
neonatal P0-3 mice, as previously described [18]. Briefly,
brain tissue was dissociated with trypsin (Invitrogen,
Darmstadt, Germany) for 20 min at 37°C. After mechanical
dissociation, cells were plated in 75-cm2 culture flasks inDMEM (Invitrogen, Darmstadt, Germany) supplemented
with 10% FBS and penicillin/streptomycin. After 1 week in
culture, mixed glial cultures were shaken for 30 min at
180 rpm. The supernatant containing >95% microglia was
plated on poly-d-lysine-coated (BD Biosciences, San Jose,
USA) glass coverslips. Microglia were maintained in
DMEM with 10% FBS.
Primary cultures of cortical neurons were generated
from forebrains of E17 mice. Cortices were dissociated
by trituration with papain (Worthington, Lakewood,
USA) in EBSS (Invitrogen, Darmstadt, Germany) for
5 min at 37°C. Subsequently, cells were resuspended in
0.25% trypsin inhibitor and 0.25% BSA (both obtained
from Sigma-Aldrich, Munich, Germany) in EBSS, and
incubated at 37°C for 5 min. Cells were pelleted by cen-
trifugation at 1000 × g for 5 min. The cell concentration
was adjusted to 1 × 106 cells/ml in MEM with GlutaMAX
medium (Invitrogen, Darmstadt, Germany) supplemented
with 10% FBS and penicillin/streptomycin. A total of 5 ×
105 cells/24-well were plated onto poly-d-lysine-coated glass
slides (BD Biosciences, San Jose, USA) and were maintained
in humidified 5% CO2/95% air at 37°C. Immediate immu-
nostaining revealed 90–95% purity for neurons.
At day 3 after plating of neurons half of the media per
well was replaced by 60.000 microglia in DMEM.
Co-cultures of microglia and neurons were incubated
with the respective agents after a further 12 h.
Oli-neu precursor cell line and co-cultures containing
Oli-neu cells and microglia
Oli-neu cells were generously provided by Dr. J. Trotter
(Institute of Molecular Biology, Johannes Gutenberg-
University, Mainz, Germany) [64] and were cultured in
DMEM (Invitrogen, Darmstadt, Germany) supplemented
with 10% FBS and penicillin/streptomycin. At 12 h after
plating of 6.000 Oli-neu cells half of the media per 24-well
was replaced by 60.000 microglia in DMEM. Co-cultures
of microglia and Oli-neu cells were incubated with the
respective agents after a further 12 h.
Intrathecal injection into mice
Intrathecal injection into mice was performed as
described previously [43]. In brief, male C57BL/6,
TLR4−/−, or MyD88−/− mice (~20 g) were anesthetized
with i.p. ketamine (100 mg/kg; AllemanPharma, Pfullingen,
Germany) and xylazine (16 mg/kg; Bayer, Leverkusen,
Germany). A skin incision was made to expose the lumbar
spine. Using a 30-gauge needle and a microliter syringe,
40 μl of water alone, LPS, HSP60, or SA solution, as
indicated, were slowly injected into the spinal canal at
vertebrae L2 or L3. The skin incision was closed
using dermal clips. Animals were then allowed to wake up
and given free access to food and water. Absence of par-
esis and adequate waking were verified. For toxicity
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(Enzo Life Sciences, Lörrach, Germany) was injected.
The contamination with LPS of the HSP60 preparation as
declared by the manufacturer was <50 EU/mg and ≤1.67
EU/mg, as determined by an independent laboratory
specializing in endotoxin testing and published in previous
work (Mikrobiologisches Labor, Münster, Germany; see
also [17]). Human serum albumin (SA, Ultra-Low endo-
toxin, HumanZyme, Chicago, USA, 40 μg) was used as
control protein with a similar molecular weight as HSP60
(60 kDa). LPS (0111:B4) was purchased from Enzo Life
Sciences, Lörrach, Germany.
Model of experimental murine stroke
Stroke was induced by middle cerebral artery occlusion
(MCAo) in C57BL/6 J male mice at 10–12 weeks of age,
as described previously [65]. Briefly, under isoflurane
(Abott, Wiesbaden, Germany) anaesthesia in a 1:2 mixture
of oxygen/nitrous oxide a monofilament was inserted into
the common carotid artery, advanced to the origin of the
MCA, and left in place for 60 min until reperfusion. In
sham-operated animals, the monofilament was also
inserted and advanced to the MCA, but was withdrawn
immediately, thereby avoiding ischemia. Mice were kept
in heated cages for the next 2 h, and rectal temperature
was measured regularly. Cerebrospinal fluid (CSF)
samples were obtained, as previously described [43], after
one day. In brief, a skin incision was made over the head
and neck. After dissection of the suboccipital muscles, the
cisterna magna was punctured and CSF withdrawn using a
27-gauge butterfly cannula connected to a microliter
syringe. Brains were removed, snap frozen in methylbutane,
and stored at −80°C until further processing.
Immunocytochemistry and immunohistochemistry
Seventy-two hours after intrathecal injection or 24 h
after MCAo, mice were deeply anesthetized with i.p.
ketamine and xylazine and then fixed by transcardial
perfusion with PBS followed by 4% paraformaldehyde
(PFA) in phosphate buffered saline (PBS). Forebrains were
post-fixed in 4% paraformaldehyde in PBS overnight, then
cryoprotected in a row of 10%, 20%, and 30% sucrose.
Cryostat coronal sections (15 μm) were thaw-mounted on
coated glass slides. Representative brain sections (level 1:
interaural 6.60 mm; level 2: 5.34 mm; level 3: 3.94 mm;
level 4: 1.86 mm; level 5: −0.08 mm) or cell cultures were
fixed with 4% PFA, washed with PBS, and treated with
blocking solution (5% normal goat serum) for 1 h. They
were then incubated with the respective primary antibody:
anti-NeuN, anti-neurofilament (200 kDa, clone RT97),
anti-myelin basic protein (MBP), anti-glial fibrillary acidic
protein (GFAP), or anti-adenomatous polyposis coli
(APC) (all purchased from Merck Millipore, Darmstadt,
Germany), anti-HSP60 (Enzo Life Sciences, Lörrach,Germany), anti-Ki67 (ab 16667, Abcam, Cambridge,
UK), anti-Iba1 (WAKO, Neuss, Germany), anti-CD11b
(eBioscience, Frankfurt, Germany) or the isolectin IB4
(Invitrogen, Carlsbad, USA) overnight at 4°C. Subsequently,
sections or cell cultures were incubated with the relevant
secondary antibody (all purchased from Jackson Immuno
Research, West Grove, USA) for 1 h at room temperature.
TUNEL staining of co-cultures and the CNS cortex was
conducted after 3 d of incubation and 5 d after intrathecal
injection, respectively, using the Apoptaq Plus Fluorescein
In Situ Apoptosis Detection Kit, following the instruction
manual (Merck Millipore, Darmstadt, Germany). DAPI
staining was performed as previously described [18].
Immunofluorescence images were obtained using an
Olympus BX51 microscope.
Quantification of CNS cells in brain sections
Viability of neurons and oligodendrocytes in the brain’s
cortex was analyzed by quantifying NeuN-positive and
APC-positive cells, respectively, in six fields (x600) at level
four of five representative sections of each brain. The
mean was calculated, which is expressed as NeuN-positive
or APC-positive cells per mm2, and each group is dis-
played with the median.
For analysis of apoptotic cells, brain sections were
stained by TUNEL and DAPI. TUNEL-positive and
DAPI-positive nuclei were counted in the cerebral cortex
from representative levels one to five after visual verifica-
tion of apoptotic hallmarks such as shrinkage and fragmen-
tation, and the sum per field was calculated. Each group is
displayed with the median.
Microglia and astrocytes were quantified by staining brain
sections with anti-Iba1 and anti-GFAP antibodies, respect-
ively. Iba1-positive or GFAP-positive cells were quantified
in three fields per hemisphere at level four of five represen-
tative sections of each brain, and the mean was calculated,
which is expressed as Iba1-positive or GFAP-positive cells
per mm2. Each group is displayed with the median.
Stereological analysis of brain sections
Stereological quantification of neurons and oligodendroglia
in mice was performed using the CellSenseTM software pro-
vided by Olympus. For experiments involving intrathecal
injections, six fields (×60) in the cortex of five representa-
tive brain sections stained with NeuN or APC antibody per
animal were analyzed by quantifying NeuN-positive or
APC-positive objects and determining the percentage area
of NeuN-positive or APC-positive region of interest (ROI),
as indicated. The threshold was set to 400 dpi (NeuN+) or
150 dpi (APC+). For analysis of TUNEL-stained cells,
whole cortices of five representative brain sections per ani-
mal were analyzed by quantifying TUNEL-positive objects
and the percentage of TUNEL-positive region of interest
(×20, threshold 20 dpi).
Rosenberger et al. Molecular Neurodegeneration  (2015) 10:5 Page 17 of 19Measurement of fluorescence intensity in immunostained
brain sections
For Iba1, GFAP, and MBP reactivity measures (mean fluor-
escence intensity per area) DAPI staining was used as
reference. Mean fluorescence intensity of Iba1, GFAP, or
MBP as assessed by Image J software was divided by the
mean fluorescence intensity of DAPI from the same scan
to assure technical accuracy. Representative brain slices
containing the cortical area (20 μm) per animal were
scanned using a confocal laser scanning microscope (Leica
TCS SPE, Wetzlar, Germany). Z-stacks were analysed using
Image J software by a person blind to the sample identity.
Real-time PCR
One brain hemisphere was homogenized in 1 ml TRIzol®
with an Ultra-Turrax® at 21500 rpm for 30 sec. The hom-
ogenate was centrifuged at 12000 x g and 4°C for 15 min.
DNA was removed with RQ1 RNase-free DNase and
UltraPure™ phenol:chloroform:isoamyl alcohol. For synthe-
sis of cDNA from 1 μg RNA, random hexamers were used
with MMLV-RT (Promega, Mannheim, Germany). SYBR®
Green-based quantitative real-time PCR was per-
formed with the RT2 qPCR Primer Assays (SABiosciences
Corporation, Frederick, USA) according to the manufac-
turer’s manual with the RT2 Real-Time™ PCR protocol
(#1) and the ABI7500 default dissociation stage.
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was
used as a housekeeping gene for control. For statistics dCT
values (CTGOI-CTHKG) were log2-transformed according
to [66]. Fold exchange (2-(ddCT)) relative to the control was
calculated using the median of each group. P values and
stars indicate statistical significance, fold change values
<0.5 and >2 indicate biological significance.
Cytokine bead assay
Cytokine bead assay was performed with the FlowCytomix
System (eBioscience, Frankfurt, Germany) according to the
manufacturer’s manual. One half of a brain per mouse was
lysed in 50 mM Tris pH 7.4 with cOmplete Ultra Tablet
(Roche, Basel, Switzerland) with an Ultra-Turrax (5 section
at 17500 rpm) on ice. Lysates were centrifuged at 10000 x
g, 4°C for 30 min. Protein levels in supernatants were
measured by BCA Protein Assay (Pierce, Rockford, USA).
Analysis of NO content
The amount of nitric oxide in one brain hemisphere was
determined by the standard Griess’ reaction, as previ-
ously described [17].
HSP60 and Il-1β ELISA
Amounts of HSP60 in the CSF of mice and Il-1β in
murine brain lysates were determined by ELISA according
to the manufacturer’s respective manuals (Enzo LifeSciences, Lörrach, Germany, and BD Biosciences,
Heidelberg, Germany, respectively).
Western blot
Lysates (10 μg of protein) of primary neurons, microglia,
and Oli-neu cells or lysates of brain hemispheres of
MCAo-treated and sham-operated mice, as indicated,
were applied to a 10% SDS-PAGE gel. HSP60 and neuronal
nuclei were detected by immunoblotting using a mouse
monoclonal antibody against HSP60 (Enzo Life Sciences,
Lörrach, Germany) and neuronal nuclei (NeuN, Merck
Millipore, Darmstadt, Germany), respectively. The mouse
monoclonal antibody against synaptophysin was generously
provided by Dr. M. Hoeltje (Charité-Universitaetsmedizin
Berlin, Germany). Protein signals were visualized by
enhanced chemiluminescence detection, as described
previously [17], and intensities of the signals were
quantified by Image J software.
Statistical analysis
Data are expressed as indicated in the figure legends.
Statistical differences between treatment groups were
determined using Mann–Whitney U test, one-way and
two-way ANOVA, or Kruskal Wallis test, as indicated.
Differences were considered statistically significant when
p < 0.05.
Additional files
Additional file 1: Figure S1. Stereological analysis of neuronal and
oligodendrocyte injury and loss in the cerebral cortex in response to
intrathecal HSP60. (A-D) Forty micrograms of HSP60 or 40 μg of SA were
injected intrathecally into 8-12 week-old C57BL/6J (WT, HSP60 n=11, SA
n=8), TLR4-/- (HSP60 n=11, SA n=8), and MyD88-/- (HSP60 n=11, SA n=8)
mice. Naïve mice received no injection (WT n=6, TLR4-/- n=4, MyD88-/-
n=4). Injection of LPS into WT mice served as a positive control for TLR4
activation (n=10). Injection of water into WT mice served as a carrier
control (n=7). After 3 d, the cerebral cortex was immunostained with
NeuN antibody (A, B) or stained by TUNEL assay (C, D). Subsequently,
stereological analysis was performed by (A, C) quantification of NeuN+
or TUNEL+ objects and (B, D) determination of the percentage of the
area of NeuN+ or TUNEL+ ROI (region of interest). Results are presented
as mean +/- SD, Mann-Whitney U test for indicated groups. (E, F) Three
days after intrathecal injection of 40 μg HSP60 or 40 μg SA (control) coronal
brain sections of C57BL/6J (WT, HSP60 n=4, SA n=4), TLR4-/- (HSP60 n=4, SA
n=4), and MyD88-/- (HSP60 n=4, SA n=4) mice were immunostained with an
antibody against APC. Subsequently, stereological analysis was performed by
(E) quantification of APC+ objects and (F) determination of the percentage
of the area of APC+ ROI. Results are presented as mean +/- SD,
Mann-Whitney U test for indicated groups.
Additional file 2: Figure S2. Stereological quantification and intensity
analysis of HSP60 expression in the brain of mice treated with MCAo.
Ipsilateral area of infarct (ipsi), respective contralateral area (co), and
lesion-associated region (lar) in brains of C57BL/6J mice treated with
MCAo (n=4) were immunostained after 1 d with an HSP60 antibody and
with DAPI. Sham-operated animals served as a negative control (n=4).
Subsequently, stereological analysis was performed by (A) quantification
of HSP60+ objects and (B) determination of the percentage of the area of
HSP60+ ROI (region of interest). (C) Analysis of mean HSP60+ fluorescence
intensity in the brain regions of the animals named above. (A-C) Results are
presented as mean +/- SD, Mann-Whitney U test for indicated groups.
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